about
Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cellsDifferential MAP kinases activation during semaphorin3A-induced repulsion or apoptosis of neural progenitor cellsHow a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II.Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium.Rapid screening and confirmatory methods for biochemical diagnosis of human prion disease.Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study.Magnetic Resonance Imaging of Cerebral Aspergillosis: Imaging and Pathological CorrelationsIntraoperative Probe-Based Confocal Laser Endomicroscopy in Surgery and Stereotactic Biopsy of Low-Grade and High-Grade Gliomas: A Feasibility Study in Humans.CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.Pseudotumoral presentation of cerebral amyloid angiopathy-related inflammation.CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling.Anti-NMDA receptor antibody encephalitis and neuroendocrine pancreatic tumor: Causal link?Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation.Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.Characteristics of cerebellar glioblastomas in adults.Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.COB231 targets amyloid plaques in post-mortem human brain tissue and in an Alzheimer mouse model.Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium.Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium.Dynamic susceptibility contrast perfusion imaging in biopsy-proved adult medulloblastoma.Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy.Identification of novel recurrent ETV6-IGH fusions in primary central nervous system lymphoma.[Neuropathology of sudden infant death syndrome: Review of the literature and proposal of a protocol for neuropathological examination].Liponeurocytoma of the cerebello-pontine angle.P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients.Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease.How reliable are 40 MHz IVUS and 64-slice MDCT in characterizing coronary plaque composition? An ex vivo study with histopathological comparison.Characteristics of H3 K27M-mutant gliomas in adults.[Pulmonary MALT lymphoma revealing AIDS].P08.39 Characteristics of adults’ gliomas with H3-K27M mutations.Molecular classification of adult gliomas: recent advances and future perspectivesAre molecular subgroups of medulloblastomas really prognostic?Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter MutationsAssessment of α-Synuclein Pathology: A Study of the BrainNet Europe ConsortiumInter-laboratory comparison of neuropathological assessments of β-amyloid protein: a study of the BrainNet Europe consortiumErratum to: Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium
P50
Q24550871-2A186DD4-B079-4D91-BC21-6337C7A46ED0Q28256115-C010A30E-039C-4211-BF17-F1F387056C7FQ33449817-36666199-B7A6-433C-B946-E9931EC48308Q33451012-9C557027-636C-4AFA-85DD-A616A25AEB20Q34629592-6468A0FC-EF03-472B-90A9-28C073C22826Q35627827-ED6ACF8A-53CB-4528-843C-96D4B661C7B2Q35632339-58EAB769-6E59-4311-A88C-02FCB49DD723Q35994988-D6CF4331-DA07-4369-BD52-010997A7B013Q36137311-2884782A-C606-4271-80F9-97FC2A9BBD99Q36288275-1EE37DC0-DA85-454A-96F8-E5D39F91ACA7Q37536763-89432CE8-3844-40A6-AF2B-48CB9FE7D697Q38833788-D08916FE-CB99-4A5A-ABC9-FB8D3AB889ECQ38858865-4695AE07-1530-489B-B3C6-75EB2244A2C4Q42034751-7C5BC10B-14F4-49E4-B443-592B88468868Q44007575-3873ED4F-C539-4B82-B275-6757713F276FQ46495403-D96FA416-FA40-4493-8CF1-1EFEFAAD9C92Q47804454-623B500F-BFFA-41BE-9D24-D594058D5121Q48034442-E314A1CD-D4EE-498B-A44C-DBA76CA43ED3Q48192532-1EFCEC74-8443-43B2-B4CE-24482D650286Q48295109-AE60B9E7-F979-4E5A-AB83-AEE5CF26FBA2Q48513032-8E394D3F-4834-4651-B085-E1983BA805DFQ48529691-07E08111-4467-412B-83A9-2B2635A9FE7AQ48683712-15758948-F28B-4CBD-B644-78A3F3A81342Q48694416-08EAE516-A51C-412D-B62F-CC8AD56F22AFQ49505406-0B41A17E-8530-417B-8143-DC786A2A8AC9Q50061613-6606F082-0E03-427B-BFEC-B42C973EE1E8Q50075125-C37267C4-249E-4F0D-B13B-929C1210214DQ50079346-382F925A-E22D-46E4-AFB3-61FD25A3E037Q50357688-21B28EDB-2E98-43CD-B8BA-8027D65364BDQ50760096-46AF7D77-FBE4-4D6E-850E-6578FC784927Q53315883-C0A3C9F0-F048-4B26-BFAC-D06C4E0D65E8Q53769248-48091E3E-4573-4D60-87BF-E75BD487F59FQ54119025-0C14FEEA-EEC1-4E63-92E6-F15ADCC38EE9Q55017831-16A581CE-EB63-418B-94DD-9B1DB8DEB2E6Q57167586-B4565F3F-98BB-4529-AD09-88F1289498E0Q57294048-F1C7035D-CBA6-4D91-985E-8AFD05CEE018Q58586915-C3EE7212-8B8B-48F8-9ECB-1C39AA38BCEDQ59690255-8419D5CB-BD1F-48D3-BDBA-DCF91EAB17CBQ59690267-D510CB68-169E-4BE9-B2E7-F52D3B82FF4DQ59691208-637CAEFF-D54B-4BFB-97D4-B5F09F0BB5D5
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
D Meyronet
@en
D Meyronet
@nl
type
label
D Meyronet
@en
D Meyronet
@nl
prefLabel
D Meyronet
@en
D Meyronet
@nl
P31
P496
0000-0001-9943-4578